Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 55 out of 100. TREM2 and immune genetics

Topic: Brain proteins, microglia and lab models

Plain-language summary

Alzheimer's disease (AD) is characterized by plaques containing amyloid-β (Aβ) and neurofibrillary tangles composed of aggregated, hyperphosphorylated tau. Beyond tau and Aβ, evidence suggests that microglia play an important role in AD pathogenesis. Rare variants in the microglia-expressed triggering receptor expressed on myeloid cells 2 (TREM2) gene increase AD risk 2- to 4-fold.

What this study adds

Evidence grade: Low

This 2020 research paper studied how the TREM2 variant R47H affects brain inflammation ("gliosis") and nerve-cell loss driven by tau, the protein that forms tangles in Alzheimer's disease. Our stored summary covers only the background, which notes that rare TREM2 variants raise Alzheimer's risk "2- to 4-fold" and that this is "likely" because microglia respond less to amyloid.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Gratuze, M., Leyns, C. E., Sauerbeck, A. D., St-Pierre, M. K., Xiong, M., Kim, N., et al. (2020). Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. The Journal of clinical investigation. https://doi.org/10.1172/jci138179

Vancouver

Gratuze M, Leyns CE, Sauerbeck AD, St-Pierre MK, Xiong M, Kim N, et al. Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration. The Journal of clinical investigation. 2020. doi:10.1172/jci138179. PMID: 32544086.

BibTeX

@article{gratuze2020-32544086,
  author  = {Gratuze, M. and Leyns, C. E. and Sauerbeck, A. D. and St-Pierre, M. K. and Xiong, M. and Kim, N. and Serrano, JR. and MÈ, Tremblay and others},
  title   = {{Impact of TREM2R47H variant on tau pathology-induced gliosis and neurodegeneration}},
  journal = {The Journal of clinical investigation},
  year    = {2020},
  doi     = {10.1172/jci138179},
  pmid    = {32544086},
  url     = {https://doi.org/10.1172/jci138179}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This 2020 research paper studied how the TREM2 variant R47H affects brain inflammation ("gliosis") and nerve-cell loss driven by tau, the protein that forms tangles in Alzheimer's disease. Our stored summary covers only the background, which notes that rare TREM2 variants raise Alzheimer's risk "2- to 4-fold" and that this is "likely" because microglia respond less to amyloid. It does not include what the study found, what it was done in, or how large it was, so read the original paper before drawing any conclusion.

Study details

How this study scored 55/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 5 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 55 of 100.55 of 100 points earned45 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (The Journal of clinical investigation)
Journal's citation record 4 / 4 Journal of Clinical Investigation: journal h-index 706 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 5 / 7 Cited 248 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 31.0 citations a year over 8 year(s) since 2020
Impact for its field and year 5 / 6 Cited 21.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 37 other studies in this library
Still being cited 3 / 4 Cited 81 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author David M. Holtzman: h-index 206 (OpenAlex, whole career)
Institution's track record 2 / 3 Washington University in St. Louis: institution h-index 1,962 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32544086)
Free to read 0 / 2 Behind a paywall — scores zero
Total 55 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 42.

Later studies that cite this one

37 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in TREM2 and immune genetics from nearby years

Also tagged “r47h”

363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on TREM2 and immune genetics

See all studies in TREM2 and immune genetics →